Abstract
Although targeted immunomodulatory medications are increasingly utilized for inflammatory skin conditions like plaque psoriasis, little is known of the trends in the adoption of newly Federal Drug Administration (FDA)-approved immunomodulators by dermatologists. We performed a retrospective, cross-sectional analysis of Medicare Part D Prescriber datasets to identify dermatologists filing Medicare prescription claims for immunomodulatory drugs FDA-approved for plaque psoriasis between 2013 and 2018. Differences in dermatologist characteristics were determined between dermatologists prescribing a psoriasis treatment within two years of its FDA approval, “early adopters” and non-prescriber dermatologists over the same time period. Biologics approved for psoriasis from 2013 to 2018 included certolizumab pegol, secukinumab, brodalumab, ixekizumab, guselkumab, and apremilast. Early adopter dermatologists (n = 783) accounted for 5% of all Medicare Part D prescribing dermatologists. Early adopters were more likely to be male, in practice longer, and had a greater number of average annual beneficiaries than dermatologists who did not. Only six (< 1%) early adopters practiced in a small town or rural areas. We believe these data show that the adoption of novel biologic treatments for psoriasis by dermatologists to Medicare beneficiaries may be associated with clinician experience and practice volume. Additionally, we identified low absolute numbers of dermatologists prescribing biologics overall in non-metropolitan areas, which may represent delayed access to novel psoriasis treatments for many Medicare beneficiaries.
References
Singh P, Silverberg JI (2020) Real-world trends in biologic, oral systemic, and phototherapy in US patients with psoriasis or psoriatic arthritis. J Am Acad Dermatol 83(1):256–257
Gronbeck C, Feng PW, Feng H (2021) Trends in Medicare Part D prescription claims for biologic and nonbiologic immunosuppressive medications by dermatologists. J Am Acad Dermatol 84(3):848–851
Feng H, Cohen JM, Neimann AL (2019) Access to injectable biologic medications by medicare beneficiaries: geographic distribution of US dermatologist prescribers. J Dermatolog Treat 30(3):237–239
Consumer Price Index Inflation Calculator. 2021; Online CPI Inflation Calculator]. Available from: https://www.bls.gov/data/inflation_calculator.htm
Funding
None.
Author information
Authors and Affiliations
Contributions
OD and PS wrote the main manuscript text and OD prepared all figures and tables. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declared that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Dean, O., Tausk, F. & Singh, P. Adoption of newly FDA-approved targeted immunomodulatory therapies by dermatologists: a cross-sectional analysis of Medicare Part D claims from 2013 to 2018. Arch Dermatol Res 315, 673–676 (2023). https://doi.org/10.1007/s00403-022-02422-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-022-02422-3